An integrated model of FTO and METTL3 expression that predicts prognosis in lung squamous cell carcinoma patients

Autor:	Siyao Liu, Zhaojie Han, Kun Zhang, Fuchun Zeng, Hongmei Zhao
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty Lung Framingham Risk Score Receiver operating characteristic RNA methylation business.industry Lung squamous cell carcinoma General Medicine Nomogram medicine.anatomical_structure Internal medicine medicine Copy-number variation Risk assessment business
Zdroj:	Annals of Translational Medicine. 9:1523-1523
ISSN:	2305-5847 2305-5839
DOI:	10.21037/atm-21-4470
Popis:	Background Lung squamous cell carcinoma (LUSC) approximately accounts for a third of lung cancers. However, the role of N6-methyladenosine (m6A) in LUSC remains largely unknown according to previous studies. Methods In this study, we investigated the mutations, copy number variants (CNVs), expression of 20 m6A RNA methylation regulators, and clinical data from The Cancer Genome Atlas-LUSC (TCGA-LUSC). These data were used for the training cohort of screening potential biomarkers. The prognostic model of m6A RNA methylation regulators was constructed. A receiver operating characteristic (ROC) analysis was undertaken to determine the area under the curves (AUCs) (for 3- and 5-year survival) for the model. Additionally, the accuracy of the two-gene model was confirmed with external data verifications. Combined two-gene model and clinincal information were performed to construct a nomogram to predict patient's prognostic risk assessment. Results Fat mass- and obesity-associated protein (FTO) and methyltransferase-like 3 (METTL3) were identified as potential prognostic biomarkers to evaluate benign and malignant tumors and prognosticate. The following prognostic model of m6A RNA methylation regulators was constructed: risk score = 0.162 × FTO - 0.069 × METTL3. Patients in low-risk group [median overall survival (mOS), 43.4 months] had longer survival than those with high-risk (mOS, 67.3 months) with P=0.0023. The smoking grade and risk score could be independent prognostic factors (P=0.00098 and P=0.0014, respectively). Ultimately, a nomogram was developed to assist clinicians to predict clinical outcomes. Conclusions FTO and METTL3 are potential prognostic biomarkers of LUSC. The two-gene model's use of prognostic risk scores may provide guidance in the selection of therapeutic strategies.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4f42c19860d3e7dd264c3e4650bedb73 https://doi.org/10.21037/atm-21-4470 Zobrazit plný text záznamu